News & Events

Press Releases

Feb 24

Efficacy and Safety Data from Solid Biosciences’ Ongoing IGNITE DMD Phase I/II Clinical Trial to be Presented at the 2021 MDA Clinical & Scientific Conference

- IGNITE DMD Principal Investigator, Dr. Barry Byrne , to present efficacy and safety data from the ongoing IGNITE DMD trial on Thursday, March 18 - -Company to host external key opinion leaders at a symposium to discuss Real World Outcomes Measures in Duchenne Muscular Dystrophy during the

Read More
Feb 17

Solid Biosciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass. , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider , PhD, Chief Technology Officer, and Cathryn Clary , MD, MBA,

Read More
Jan 06

Solid Biosciences to Present at 39th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. , Jan. 06, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot , Chief Executive Officer, President and Co-Founder, will present

Read More